Overview

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

Status:
Completed

Trial end date:
2007-05-01

Target enrollment:
0

Participant gender:
All

Summary

Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Cumberland Pharmaceuticals
Theravance Biopharma Antibiotics, Inc.

Treatments:

Methicillin
Telavancin
Vancomycin

Criteria

Inclusion Criteria:

- Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours
of continuous stay in an inpatient acute or chronic care facility or acquired within 7
days after being discharged from a hospitalization of greater than or equal to 3 days
duration.

Exclusion Criteria:

- Received more than 24 hours of potentially effective systemic (IV, IM or PO)
antibiotic therapy for Gram-positive pneumonia immediately prior to randomization.